TY - JOUR
T1 - Melatonin and bone-related diseases
T2 - an updated mechanistic overview of current evidence and future prospects
AU - Bagherifard, Abolfazl
AU - Hosseinzadeh, Azam
AU - Koosha, Fereshteh
AU - Sheibani, Mohammad
AU - Karimi-Behnagh, Arman
AU - Reiter, Russel J.
AU - Mehrzadi, Saeed
N1 - Publisher Copyright:
© 2023, International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.
PY - 2023
Y1 - 2023
N2 - Purpose: Bone diseases account for an enormous cost burden on health systems. Bone disorders are considered as age-dependent diseases. The aging of world population has encouraged scientists to further explore the most effective preventive modalities and therapeutic strategies to overcome and reduce the high cost of bone disorders. Herein, we review the current evidence of melatonin’s therapeutic effects on bone-related diseases. Methods: This review summarized evidences from in vitro, in vivo, and clinical studies regarding the effects of melatonin on bone-related diseases, with a focus on the molecular mechanisms. Electronically, Scopus and MEDLINE®/PubMed databases were searched for articles published on melatonin and bone-related diseases from inception to June 2023. Results: The findings demonstrated that melatonin has beneficial effect in bone- and cartilage-related disorders such as osteoporosis, bone fracture healing, osteoarthritis, and rheumatoid arthritis, in addition to the control of sleep and circadian rhythms. Conclusion: A number of animal and clinical studies have indicated that various biological effects of melatonin may suggest this molecule as an effective therapeutic agent for controlling, diminishing, or suppressing bone-related disorders. Therefore, further clinical studies are required to clarify whether melatonin can be effective in patients with bone-related diseases.
AB - Purpose: Bone diseases account for an enormous cost burden on health systems. Bone disorders are considered as age-dependent diseases. The aging of world population has encouraged scientists to further explore the most effective preventive modalities and therapeutic strategies to overcome and reduce the high cost of bone disorders. Herein, we review the current evidence of melatonin’s therapeutic effects on bone-related diseases. Methods: This review summarized evidences from in vitro, in vivo, and clinical studies regarding the effects of melatonin on bone-related diseases, with a focus on the molecular mechanisms. Electronically, Scopus and MEDLINE®/PubMed databases were searched for articles published on melatonin and bone-related diseases from inception to June 2023. Results: The findings demonstrated that melatonin has beneficial effect in bone- and cartilage-related disorders such as osteoporosis, bone fracture healing, osteoarthritis, and rheumatoid arthritis, in addition to the control of sleep and circadian rhythms. Conclusion: A number of animal and clinical studies have indicated that various biological effects of melatonin may suggest this molecule as an effective therapeutic agent for controlling, diminishing, or suppressing bone-related disorders. Therefore, further clinical studies are required to clarify whether melatonin can be effective in patients with bone-related diseases.
KW - Chondrosarcoma
KW - Ewing’s sarcoma
KW - Fibromyalgia
KW - Giant cell tumor
KW - Gout
KW - Melatonin
KW - Osteoarthritis
KW - Osteoporosis
KW - Osteosarcoma
KW - Pharmacology
KW - Rheumatoid arthritis
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85163767717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163767717&partnerID=8YFLogxK
U2 - 10.1007/s00198-023-06836-1
DO - 10.1007/s00198-023-06836-1
M3 - Review article
C2 - 37393580
AN - SCOPUS:85163767717
SN - 0937-941X
VL - 34
SP - 1677
EP - 1701
JO - Osteoporosis International
JF - Osteoporosis International
IS - 10
ER -